What is dengue?

Dengue is the most prevalent mosquito-borne virus, and it is a substantial public health and economic burden. There are no antiviral therapies approved for the treatment of dengue. Dengue is a feverish, painful and debilitating mosquito-borne infection caused by an RNA virus that may result in a severe, potentially fatal clinical syndrome called dengue hemorrhagic fever. There are five commonly recognized serotypes of dengue virus. An infection with one serotype does not protect against the others.

It is not possible to accurately predict who is at risk for a severe or fatal form of dengue infection, though a high level of virus in the blood and previous dengue infection are risk factors for clinically severe dengue infections. It is estimated that dengue accounts for up to 400 million infections a year globally, of which 100 million people get sick from the infection1 and 500,000 cases develop into life-threatening dengue hemorrhagic fever. Dengue infection is currently endemic in equatorial regions of the world, including Puerto Rico, Southeast Asia, Latin America and the Pacific Islands.

Although dengue rarely occurs in the U.S. and other areas outside the endemic regions, intercontinental jet transport, immigration, tourism, military operations and mosquito migration are increasing the direct effect of dengue on the global population. The mosquito vector that transmits dengue infection is becoming increasingly common in the southern U.S., and sporadic dengue infections have been recognized in the American Gulf states.

The World Health Organization has called dengue the most important mosquito-borne viral disease in the world. The U.S. Food and Drug Administration, together with other governmental and non-governmental agencies, recognize dengue as a substantial and growing global public health burden. Dengue is defined as a tropical disease under the U.S. Food, Drug and Cosmetic Act.

1. Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Vector-Borne


AT-752 is an orally administered direct-acting antiviral derived from Atea’s purine nucleotide prodrug platform and is being developed for the treatment of dengue fever.

A mosquito biting into human skin.